

Conventional versus minimally invasive extracorporeal circulation in patients undergoing cardiac surgery: a randomised controlled trial

Submission date 18/12/2017	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 18/01/2018	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 11/02/2026	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Miniaturised heart-lung machines (minimally invasive extracorporeal circulation; MiECC) have been developed with the aim of reducing the number of post-operative complications arising from using conventional heart-lung machines (CECC). Due to the variety of miniaturised systems that have been evaluated, the different types of patients and outcomes investigated, and the poor quality of previous studies, the effectiveness of MiECC in reducing post-operative complications has not been established and most hospitals continue to use CECC. Compared to CECC, using MiECC during cardiac surgery may reduce the proportion of patients having one of several serious postoperative complications (death, heart attack, stroke, gut infarction, severe acute kidney injury, reintubation, tracheostomy, mechanical ventilation for more than 48 hours, or reoperation). In addition, MiECC may reduce the amount of blood products transfused, time to discharge from the cardiac intensive care unit and hospital and the health care resources used during the hospital stay. The aim of this study is to evaluate the MiECC system and to detect if there is a reduction in risks as compared to the CECC.

Who can participate?

Adults aged 18 to 85 who are undergoing any elective or urgent coronary artery bypass surgery, aortic valve replacement or both using a heart-lung machine without circulatory arrest.

What does the study involve?

Participants are randomly allocated to one of two groups. Participants in the first group undergo surgery using the MiECC system. Those in the second group undergo surgery using CECC. Participants are followed up twice, at 30 days and at 90 days after surgery to look at the serious adverse events and their health quality of life.

What are the possible benefits and risks of participating?

The risks of having cardiac surgery are different from person to person, depending on the severity of heart disease, type of operation, age, and current state of health. Both types of heart and lung machines are used currently for heart operations in the NHS. At present, hospitals can choose either machine as there is little evidence to decide which machine is better.

Where is the study run from?

1. Bristol Royal Infirmary (UK)
2. Derriford Hospital (UK)
3. Hammersmith Hospital (UK)
4. Castle Hill Hospital (UK)
5. Royal Papworth Hospital (UK)
6. Aristotle University of Thessaloniki (Greece)
7. Inselspital, Universitätsspital Bern (Switzerland)
8. Universitätsklinikum Ulm (Germany)
9. Klinikum Braunschweig (Germany)
10. Ankara Numune Egitim Arastirma Hastanesi (Turkey)
11. Saud Al Babbain Cardiac Center (Saudi Arabia)

When is the study starting and how long is it expected to run for?

January 2017 to December 2020

Who is funding the study?

British Heart Foundation (BHF) (UK)

Who is the main contact?

Mr Jonathan Evans (Scientific), comics-trial@bristol.ac.uk

Professor Gianni Angelini – Chief Investigator

Professor Kyriakos Anastasiadis – Principal Investigator, Lead for EU-Countries

Professor Thierry Carrel – Principal Investigator, Lead for Non-EU Countries

Contact information

Type(s)

Scientific

Contact name

Mr Jonathan Evans

Contact details

Clinical Trials and Evaluation Unit

University of Bristol

Bristol Royal Infirmary

Bristol

United Kingdom

BS2 8HW

+44 117 923 0000

comics-trial@bristol.ac.uk

Type(s)

Scientific

Contact name

Prof Kyriakos Anastasiadis

Contact details

Aristotle University of Thessaloniki.
Cardiothoracic Department
AHEPA University Hospital
S. Kyriakidi 1
Thessaloniki
Greece
546 36

Type(s)

Scientific

Contact name

Prof Thierry Carrel

Contact details

Inselspital, Universitätsspital Bern
Herz- und Gefäßchirurgie
Freiburgstrasse
Bern
Switzerland
CH-3010

Type(s)

Scientific

Contact name

Prof Andreas Liebold

Contact details

Universitätsklinikum Ulm
Klinik für Herz-, Thorax- und Gefäßchirurgie
Albert-Einstein-Allee 23
Ulm
Germany
89081

Type(s)

Scientific

Contact name

Dr Aschraf El-Essawi

Contact details

Klinikum Braunschweig
Klinik für Herz-, Thorax- und Gefäßchirurgie
Salzdahlumerstrasse 90
Braunschweig
Germany
38126

Type(s)

Scientific

Contact name

Prof Serdar Gunaydin

Contact details

Numune Egitim Arastirma Hastanesi
Kalp Damar Cerrahisi
Talatpasa blvd No:5
Ankara
Türkiye
06100

Type(s)

Scientific

Contact name

Dr Farouk Queida

Contact details

Saud Al Babbain Cardiac Center
Ghirnatah
5443 King Khalid
Dammam
Saudi Arabia
32245

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CPMS 36468

Study information

Scientific Title

Conventional versus Minimally Invasive extra-corporeal circulation in patients undergoing Cardiac Surgery: a randomised controlled trial

Acronym

COMICS

Study objectives

The primary hypothesis is that, compared to CECC, using MiECC during cardiac surgery reduces the proportion of patients experiencing post-operative morbidity.

The proposed trial will overcome most limitations of previous trials of MiECC. It will: (a) evaluate MiECC system that meet specified criteria which are used in participating centres; (b) be large enough to influence clinical practice, since it will be able to detect a worthwhile benefit in an outcome relevant to patients, surgeons and health services; (c) include a range of features to prevent bias.

Ethics approval required

Old ethics approval format

Ethics approval(s)

South West – Central Bristol Research Ethics Committee, 29/11/2017

Study design

Randomized; Interventional; Design type: Treatment, Surgery

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Cardiac surgery

Interventions

This study is a multi-centre, two-group parallel randomised controlled trial to investigate the effects of using MiECC in all patients having elective or urgent coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or CABG+AVR using extra-corporeal circulation without circulatory arrest. The research objectives are addressed by randomising participants (1:1 ratio) to have surgery using MiECC system or CECC.

Patients undergoing any elective or urgent CABG, AVR, or CABG+AVR, with extra-corporeal circulation and without circulatory arrest are invited to participate. Potential trial participants are identified from operating lists. All potential participants are sent or given an invitation letter and a PIL describing the study.

Randomisation take place as close to surgery as possible and is performed by an authorised member of the local research team not involved in post-operative data collection. Participants and members of the local research team responsible for data collection are blind to the allocation.

The intervention is applied only for the duration of extra-corporeal circulation without circulatory arrest.

Participants are followed up twice, at 30 days and 90 days after surgery: questions elicit information about SAEs experienced since discharge (including readmissions) at 30 days and HRQoL (using the EQ-5D-5L) will be assessed at both times.

Intervention Type

Other

Primary outcome(s)

Composite of post-operative serious adverse events (SAEs) are measured using questions to patients during hospital stay and at 30 days post randomisation via a postal or telephone questionnaire. All SAEs that qualify for the primary outcome will be objectively defined and validated. The following events will qualify:

1. Death
2. Myocardial infarction (MI; suspected events will be documented by serum troponin concentrations and electrocardiograph recording (ECG) and adjudicated)
3. Stroke (report of brain imaging (CT or MRI), in association with new onset focal or generalised neurological deficit)
4. Gut infarction (diagnosed by laparotomy or post mortem)
5. AKI Network criteria for stage 3 AKI [16]
6. Reintubation
7. Tracheostomy
8. Mechanical ventilation for >48 hours, including multiple episodes when separated by more than 12 hours
9. Reoperation
10. Percutaneous intervention
11. Sternal wound infection with dehiscence
12. Septicaemia confirmed by microbiology

Key secondary outcome(s)

1. All-cause mortality is measured using questionnaires 30 days after randomisation
2. Other SAEs are measured using questionnaires 30 days after randomisation
3. Units of RBC transfused up to 30 days after randomisation
4. Other blood products transfused up to 30 days after randomisation
5. Time to discharge from cardiac ICU is measured using patient notes during the index admission
6. Time to discharge from hospital is measured using patient notes following the index admission
7. Delirium in ICU, assessed with the Intensive Care Delirium Screening Checklist (ICDSC) [17] for up to 5 days; this outcome will only be collected in a subset of participating hospitals that have the capability to do so.
8. Health related quality of life is measured using the HRQoL using the EQ-5D-5L [18] up to 90 days after randomisation; responses to this instrument can be mapped on to 'valuations' for the economic evaluation
9. Health and social care resources and associated costs up to 90 days after randomisation are measured using the patient in hospital stay and again at 30 and 90 days post randomisation via a postal or telephone questionnaire

Completion date

01/12/2020

Eligibility

Key inclusion criteria

1. Age ≥ 18 and < 85 years
2. Undergoing any elective or urgent CABG, AVR surgery, or CABG+AVR surgery, using extracorporeal circulation without circulatory arrest

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

85 years

Sex

All

Total final enrolment

1071

Key exclusion criteria

1. Requirement for emergency or salvage operation
2. Requirement for major aortic surgery (e.g. aortic root replacement)
3. Contraindication or objection (e.g. Jehovah's Witnesses) to transfusion of blood products
4. Congenital or acquired platelet, red cell or clotting disorders (patients with iron deficient anaemia will not be excluded)
5. Inability to give informed consent for the study (e.g. learning or language difficulties)

Date of first enrolment

05/02/2018

Date of final enrolment

01/12/2020

Locations**Countries of recruitment**

United Kingdom

England

Germany

Greece

Saudi Arabia

Switzerland

Türkiye

Study participating centre
Bristol Royal Infirmary (Lead Centre)
Bristol Heart Institute
Bristol
England
BS2 8HW

Study participating centre
Derriford Hospital
Derriford Road
Crownhill
Plymouth
England
PL6 8DH

Study participating centre
Hammersmith Hospital
Du Cane Road
Shepherd's Bush
London
England
W12 0HS

Study participating centre
Castle Hill Hospital
Castle Road
Cottingham
England
HU16 5JQ

Study participating centre
Royal Papworth Hospital
Papworth Road
Cambridge Biomedical Campus
Cambridge
England
CB2 0AY

Study participating centre
Aristotle University of Thessaloniki
Thessaloniki

Greece
541 24

Study participating centre
Inselspital, Universitätsspital Bern
Freiburgstrasse 18
Bern
Switzerland
3010

Study participating centre
Universitätsklinikum Ulm
Albert-Einstein-Allee 23
Ulm
Germany
89081

Study participating centre
Klinikum Braunschweig
Celler Str. 38
Braunschweig
Germany
38114

Study participating centre
Ankara Numune Egitim Arastirma Hastanesi
Hacettepe, Talatpaşa Blv No:44
Ankara
Türkiye
06230

Study participating centre
Saud Al Babtain Cardiac Center
Ghirnatah
5443 King Khalid
Dammam
Saudi Arabia
32245

Sponsor information

Organisation

University of Bristol

ROR

<https://ror.org/0524sp257>

Funder(s)

Funder type

Charity

Funder Name

British Heart Foundation (BHF)

Results and Publications

Individual participant data (IPD) sharing plan

At the end of the study, once analysed, anonymised datasets generated during the study can be available on request, please contact bristol-cteu@bristol.ac.uk.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		04/06/2024	11/02/2026	Yes	No
Protocol article		12/08/2020	27/02/2023	Yes	No
Basic results		29/02/2024	29/02/2024	No	No
Plain English results			21/07/2023	No	Yes
Protocol file	version 3.0		20/07/2023	No	No